Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant.

Journal Article (Journal Article)

Pancreatic cancer is highly aggressive with extremely poor prognosis. Developing a pancreatic cancer specific promoter (PCSP) is one approach for pancreatic cancer gene therapy. We have modified the promoter of cholecystokinin type A receptor (CCKAR), named CCK/Mpd, which possesses a relatively high activity in pancreatic cancer cells as compared with normal cells. The CCK/Mpd promoter-driven luciferase exhibits a better tumor specific tissue distribution than the CMV promoter-driven luciferase when systemically administered in vivo. Notably, we demonstrate a treatment efficacy by using CCK/Mpd-Bik-DD/liposome in a nude mice xenograft model, suggesting the feasibility of PCSP-based gene therapy in pancreatic cancer treatment.

Full Text

Duke Authors

Cited Authors

  • Li, Z; Ding, Q; Li, Y; Miller, SA; Abbruzzese, JL; Hung, M-C

Published Date

  • May 8, 2006

Published In

Volume / Issue

  • 236 / 1

Start / End Page

  • 58 - 63

PubMed ID

  • 15953675

International Standard Serial Number (ISSN)

  • 0304-3835

Digital Object Identifier (DOI)

  • 10.1016/j.canlet.2005.05.001


  • eng

Conference Location

  • Ireland